A first trial evaluated a combination of nivolumab and amultipeptide vaccines targeting gp100, MART-1 e NY-ESO-1 in 90 patients withpretreated melanoma, either ipilimumab-naïve or refractory. The gene discussed is PMEL; the disease is melanoma.